[October 20, 2016]

Methicillin-Resistant Staphylococcus aureus (MRSA) - 5EU Drug Forecast and Market Analysis to 2024 - Research and Markets

Research and Markets has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) - 5EU Drug Forecast and Market Analysis to 2024" report to their offering.

The 5EU MRSA market as encompassing the sales of antimicrobial agents prescribed for the treatment of hospitalized MRSA skin infections, pneumonia, and bacteremia in France, Germany, Italy, Spain, and the UK. Importantly, revenues generated by these products outside of the aforementioned countries, patient populations, and clinical scenarios are beyond the scope of this analysis.

Scope

- Overview of MRSA including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in 5EU from 2014-2024.

- Analysis of the impact of key events as well the drivers and restraints affecting 5EU MRSA market.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology

3.2 Pathophysiology

3.3 Symptoms

3.4 Prognosis (News - Alert)

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.2 5EU

5 Competitive Assessment

5.1 Overview

5.2 Product Profiles - Glycopeptides and Lipoglycopeptides

5.3 Product Profiles - Lipopeptides

5.4 Product Profiles - Oxazolidinones

5.5 Product Profiles - Cephalosporins

5.6 Product Profiles - Glycylcyclines

5.7 Other Antimicrobial Agents

6 Unmet Need and Opportunity

6.1 Overview

6.2 Drugs with Demonstrated Efficacy in Difficult-to-Treat Patient Populations

6.3 Expand Breadth of Clinical Data Outside of Skin Infections

6.4 Physician Education

6.5 Antibiotics with More Convenient Formulations and Dosing Schedules

6.6 Innovative Approaches to Clinical Trial Design

6.7 Drugs with Novel Mechanisms of Action

6.8 More Affordable Therapies

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Late-Stage Clinical Development

7.2.1 Delafloxacin (RX-3341)

7.2.2 Solithromycin (CEM-101)

7.2.3 Omadacycline (PTK-0796)

7.2.4 KRP-AM1977X

7.2.5 Taksta (fusidic acid, oral tablets)

7.2.6 Lefamulin (BC-3781)

7.2.7 Debio1450 (Debio1452 prodrug)

7.2.8 Brilacidin

7.3 Other Promising Products in Clinical Development

8 Market Outlook

9 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/qvb5xp/methicillinresist

View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006288/en/

[ Back To TMCnet.com's Homepage ]